WOLF, J. M.; GUBERT BORGES, B.; PEREIRA FAGUNDES, P.; DE SOUZA, V.; BRENNER, A.; PETEK, H.; MICHELON DOS SANTOS, W.; GASPARETTO MACCARI, J.; ROHSIG, V.; PARRINI MUTLAQ, M.; NASI, L. A. Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clinical and Biomedical Research, [S. l.], v. 43, n. 3, 2023. Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/129384. Acesso em: 24 jun. 2025.